Dr Lalchandani Labs Ltd
₹ 9.94
4.08%
05 Jun
- close price
About
Incorporated in 2011, Dr. Lalchandani Labs Ltd is in the business of running laboratories
for pathological investigations[1]
Key Points
- Market Cap ₹ 8.61 Cr.
- Current Price ₹ 9.94
- High / Low ₹ 21.2 / 8.87
- Stock P/E 144
- Book Value ₹ 16.3
- Dividend Yield 0.00 %
- ROCE 0.79 %
- ROE 0.50 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Stock is trading at 0.61 times its book value
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of -15.6% over past five years.
- Promoter holding is low: 32.9%
- Company has a low return on equity of -1.29% over last 3 years.
- Company has high debtors of 532 days.
- Promoter holding has decreased over last 3 years: -27.9%
- Working capital days have increased from 260 days to 461 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Service Provider
Loading peers table ...
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| 2.79 | 5.26 | 6.10 | 9.78 | 11.28 | 5.04 | 4.81 | 4.45 | 4.19 | |
| 2.17 | 4.06 | 4.84 | 7.54 | 8.81 | 4.95 | 4.59 | 3.52 | 3.50 | |
| Operating Profit | 0.62 | 1.20 | 1.26 | 2.24 | 2.47 | 0.09 | 0.22 | 0.93 | 0.69 |
| OPM % | 22.22% | 22.81% | 20.66% | 22.90% | 21.90% | 1.79% | 4.57% | 20.90% | 16.47% |
| 0.03 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 1.40 | 0.13 | 0.00 | |
| Interest | 0.16 | 0.14 | 0.18 | 0.35 | 0.60 | 0.99 | 0.38 | 0.09 | 0.02 |
| Depreciation | 0.13 | 0.35 | 0.42 | 0.52 | 0.59 | 0.66 | 0.62 | 0.56 | 0.57 |
| Profit before tax | 0.36 | 0.72 | 0.66 | 1.37 | 1.28 | -1.56 | 0.62 | 0.41 | 0.10 |
| Tax % | 25.00% | 26.39% | 28.79% | 26.28% | 28.12% | 0.00% | 0.00% | -2.44% | 30.00% |
| 0.26 | 0.53 | 0.47 | 1.01 | 0.93 | -1.56 | 0.62 | 0.42 | 0.06 | |
| EPS in Rs | 0.44 | 0.61 | 0.54 | 1.16 | 1.07 | -1.79 | 0.71 | 0.48 | 0.07 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -16% |
| 3 Years: | -6% |
| TTM: | -6% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -43% |
| 3 Years: | 27% |
| TTM: | -80% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -12% |
| 3 Years: | -18% |
| 1 Year: | -9% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | -2% |
| 3 Years: | -1% |
| Last Year: | 1% |
Balance Sheet
Figures in Rs. Crores
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2.93 | 4.33 | 4.33 | 4.33 | 4.33 | 4.33 | 4.33 | 4.33 | 8.64 |
| Reserves | 0.40 | 3.73 | 4.21 | 5.22 | 6.15 | 4.59 | 5.21 | 5.62 | 5.50 |
| 1.88 | 0.90 | 1.76 | 4.04 | 5.15 | 6.40 | 3.48 | 4.07 | 2.06 | |
| 1.00 | 1.18 | 1.63 | 1.61 | 2.49 | 2.40 | 1.97 | 1.72 | 1.40 | |
| Total Liabilities | 6.21 | 10.14 | 11.93 | 15.20 | 18.12 | 17.72 | 14.99 | 15.74 | 17.60 |
| 2.06 | 3.28 | 3.47 | 5.24 | 5.75 | 5.39 | 3.99 | 3.51 | 3.27 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.24 | 0.24 | 0.24 | 0.24 | 0.24 | 0.24 | 0.41 | 0.27 | 0.27 |
| 3.91 | 6.62 | 8.22 | 9.72 | 12.13 | 12.09 | 10.59 | 11.96 | 14.06 | |
| Total Assets | 6.21 | 10.14 | 11.93 | 15.20 | 18.12 | 17.72 | 14.99 | 15.74 | 17.60 |
Cash Flows
Figures in Rs. Crores
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| 0.58 | -0.45 | -0.10 | 1.19 | 2.01 | 0.00 | -0.22 | 0.37 | -0.76 | |
| -1.29 | -1.95 | -0.53 | -2.26 | -1.53 | -0.20 | 1.00 | 0.06 | -0.51 | |
| 1.57 | 3.51 | 0.85 | 1.71 | 0.16 | -0.23 | -1.59 | 0.58 | 2.12 | |
| Net Cash Flow | 0.85 | 1.12 | 0.23 | 0.64 | 0.64 | -0.43 | -0.81 | 1.01 | 0.84 |
| Free Cash Flow | -0.73 | -2.39 | -0.71 | -1.10 | 0.91 | -0.30 | 0.74 | 0.30 | -1.09 |
| CFO/OP | 94% | -32% | 5% | 67% | 95% | 0% | -100% | 40% | -110% |
Ratios
Figures in Rs. Crores
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 149.14 | 126.99 | 199.25 | 148.54 | 136.55 | 359.93 | 356.65 | 431.44 | 532.26 |
| Inventory Days | 167.03 | 233.36 | 158.70 | 68.75 | 191.07 | 458.51 | 255.15 | 490.47 | 306.69 |
| Days Payable | 426.86 | 406.89 | 355.48 | 97.06 | 175.15 | 404.21 | 217.94 | 365.00 | 110.15 |
| Cash Conversion Cycle | -110.69 | -46.54 | 2.47 | 120.23 | 152.47 | 414.23 | 393.86 | 556.91 | 728.79 |
| Working Capital Days | 162.22 | 167.23 | 206.43 | 104.50 | 77.98 | 188.29 | 163.91 | 156.66 | 460.82 |
| ROCE % | 12.14% | 8.72% | 14.40% | 12.87% | -3.68% | -2.68% | 2.81% | 0.79% |
Insights
In beta| Apr 2018 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Number of Collection Centers Number |
|
||||||
| Number of Self-Sufficient Laboratories Number |
|||||||
| Sample Processing Capacity Samples per hour |
|||||||
Requires Premium
Requires Premium
Extracted by Screener AI
Documents
Announcements
- Approval Of Audited Financial Results For The Half Year And Year Ended March 31, 2026 3 Jun
-
Board Meeting Outcome for Approval Of Audited Financial Statement For Half Year And Year Ended March 31, 2026
3 Jun - Board approved FY26 audited standalone results and appointed Brickwork Ratings for rights issue monitoring.
-
Announcement under Regulation 30 (LODR)-Meeting Updates
30 May - Board meeting to approve FY26 results postponed from May 30 to June 3, 2026.
-
Opening Of New Centre At Dwarka Delhi
28 May - Opened new strategic centre at Dwarka, Delhi, expected to generate about Rs. 1 crore annually.
-
Board Meeting Intimation for Consideration And Approval Of Financial Results Of The Company For Half Year And Year Ended March 31, 2026
27 May - Board meeting on May 30, 2026 to approve audited results for half year and year ended March 31, 2026.
Business Overview:[1][2][3]
DLLL is a NABL accredited company with 5 Self-sufficient Labs and 15 collection centers across Delhi/NCR. It is empaneled for CGHS (South, North and East Block), DJB, MCD, DDA etc. and provides diagnostic and related healthcare tests and services. Company owns, runs laboratories for carrying out pathological investigations of various branches of Bio-Chemistry, Hematology, Histopathology, Microbiology, Electrophoresis, Virology, Cytology, other pathological Investigations and Immunoassay, Immuno-Histochemistry, Molecular Pathology, DNA & Genetic Testing etc.